Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus sirolimus for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
ChiCTR2100045718Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ruxolitinib and sirolimus in graft-versus-host disease (GVHD) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Incidence of graft-versus-host disease, Incidence of thrombotic microangiopathy and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
ruxolitinibsirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2100045718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045718.